What Multilab does

Multilab is a Brazilian pharmaceutical manufacturer specializing in generic and similar medicines (medicamentos similares), founded in 1989 and headquartered in Campinas, São Paulo. The company is wholly owned by Grupo NC, one of the largest pharmaceutical conglomerates in Latin America. Multilab operates with approximately 550 professionals engaged in research, development, production, and distribution across multiple therapeutic classes, including analgesics, anti-inflammatories, antihistamines, scabicides, and flu/cold formulations. The portfolio spans prescription-required (tarjados) products and over-the-counter (isentos de prescrição) SKUs, with flagship brands including the Resfegripe family (flu/cold), Buprovil (ibuprofen-based analgesic/anti-inflammatory), Keltrina Plus (permethrin-based scabicide), Aleradina, and Acalmil. All products hold ANVISA Ministry of Health registrations and are produced under GMP-compliant manufacturing authorization.

The company's go-to-market is exclusively B2B2C, distributing through pharmaceutical wholesalers and retailers to reach more than 87,000 points of sale across Brazil. Multilab's commercial strategy is anchored on traditional retail pharmacy channels rather than direct-to-consumer or e-commerce platforms, with consumer-facing engagement limited to packaging information and a digital package-insert partnership with Sara (bula digital). Recent commercial activity centers on brand refreshes and line extensions rather than category expansion — including a 2025 Buprovil rebrand and the June 2026 launch of ResfeGripe Mel e Limão in sachet format.

Multilab generates revenue through one-time sales of pharmaceutical products to wholesalers and distributors, with no disclosed subscription, licensing, or platform model. Pricing is set through standard retail pharmacy channels and is not publicly disclosed. In 2025 the company achieved Great Place to Work certification (2025-2026) and proactively executed a voluntary recall of one lot of Solifenacin Succinate due to a packaging printing error, reflecting operational maturity in regulatory and quality management.

Name

Multilab

Legal name

MULTILAB INDUSTRIA E COMERCIO DE PRODUTOS FARM LTDA

Website

https://multilab.com.br

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Multilab is a Brazilian manufacturer of generic and similar medicines, owned by Grupo NC, producing prescription and OTC pharmaceuticals across multiple therapeutic classes for distribution to over 87,000 retail points of sale in Brazil.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Cold, Flu & Cough Remedies (HLAIADAB), Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN), Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)

Keywords

• Generic pharmaceuticals
• OTC medications
• Similar medicines Brazil
• Pharmaceutical manufacturing
• Flu and cold remedies

Headquarters

HQ city

São Jerônimo

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Multilab generates revenue through the manufacture and sale of generic and similar medicines (medicamentos similares), including both prescription (tarjados) and over-the-counter (isentos de prescricao) products across multiple therapeutic categories including analgesics, anti-inflammatories, antihistamines, and scabicides.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Multilab manufactures and distributes generic and similar medicines (medicamentos similares) across diverse therapeutic classes including analgesics, anti-inflammatories, antihistamines, flu/cold remedies, and scabicides. The company produces both prescription (tarjados) and over-the-counter (isentos de prescrição) pharmaceutical products, with a portfolio including Resfegripe, Buprovil, Keltrina Plus, Acalmil, and Aleradina. Products are distributed through pharmaceutical wholesalers to over 87,000 points of sale across Brazil.

Product overview

Multilab is a Brazilian pharmaceutical company with over 35 years of market experience, operating as part of Grupo NC, one of the largest pharmaceutical groups in Latin America. The company operates with approximately 550 professionals engaged in research, development, production, and distribution of medicines. Multilab maintains a broad portfolio spanning diverse therapeutic classes and pharmaceutical forms, divided into prescription-required (tarjados) and over-the-counter (isentos de prescrição) product lines. The product portfolio includes: Resfegripe family (flu/cold medications in capsule, tablet, and sachet formats including Resfegripe Sinus and ResfeGripe Mel e Limão variants); Buprovil family (ibuprofen-based anti-inflammatory, analgesic, and antipyretic medications in tablet and pediatric drops formats); Keltrina Plus (permethrin-based scabicide for scabies treatment); plus Acalmil and Aleradina OTC products. Distribution reaches over 87,000 sales points across Brazil.

Differentiator

Problem solved

Functional benefit

Brands

• ResfeGripe: Over-the-counter medication for treating symptoms of flu and colds, including nasal congestion, runny nose, fever, headache, and body aches. Available in capsule and sachet forms.
• Buprovil
• Keltrina
• Acalmil
• Aleradina

Products and services

• Resfegripe Over-the-counter medication for treating flu and cold symptoms, including nasal congestion, runny nose, fever, headache, and muscle aches. Contains paracetamol 400mg, chlorpheniramine maleate 4mg, and phenylephrine hydrochloride 4mg. Registration MS 1.1819.0268.
• Resfegripe Sinus Variant of Resfegripe specifically formulated for sinus symptoms associated with flu and colds.
• Resfegripe Mel e Limão New honey and lemon flavored variant of Resfegripe available in sachet format for flu and cold symptom relief.
• Buprovil Ibuprofen-based medication with anti-inflammatory, analgesic, and antipyretic properties. Available in 300mg and 600mg tablets. Registration MS 1.1819.0061.
• Buprovil Gotas Pediatric ibuprofen drops suspension for children, available in 50mg/ml (30ml bottle) and 100mg/ml (20ml bottle) concentrations.
• Keltrina Plus Permethrin-based scabicide and ectoparasiticide cream emulsion (50mg/ml, 5%) for treatment of scabies (sarna), presented in 60ml bottles. Registration MS 1.1819.0001.002-7.
• Acalmil Over-the-counter pharmaceutical product. Category and specific indications require further detail from product packaging.
• Aleradina Over-the-counter syrup medication targeting symptoms related to allergies.
• SUCCINATO DE SOLIFENACINA Prescription medication (10mg, 30 tablets) subject to voluntary recall (lot 4T4420) due to printing error on dosage packaging. Registration MS number available.

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Sara (Bula Digital)supportingTechnology or IntegrationMultilab partners with Sara to provide digital package insert (bula digital) services, allowing consumers to access medication information digitally through Sara's platform.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Teva Pharmaceutical Industries: Global generic pharmaceutical leader with presence across Latin America. Comparable as a broad incumbent competing in the same generic/similar OTC categories with global scale.
• Viatris (Mylan): Global generics and specialty pharmaceutical company formed by Mylan-Upjohn combination. Comparable in OTC and generic therapeutic categories with multinational distribution.
• Hypera (Hyperapharma): Largest Brazilian pharmaceutical company by revenue and a major OTC player (brands like Benegrip, Epocler). Comparable as a Brazilian incumbent in the same OTC categories Multilab competes in.

Direct peers

• EMS: Brazil's largest pharmaceutical company by units sold and a leading generic/similar medicines manufacturer. Directly comparable as a Brazilian OTC and generic competitor sharing Grupo NC's Mercado Farma distribution platform referenced on Multilab's own site.
• Cimed: Major Brazilian generic and OTC pharmaceutical manufacturer with broad retail distribution. Highly comparable to Multilab in target categories (analgesics, cold/flu, allergy) and consumer pricing positioning in Brazil.
• Aché Laboratórios: Brazilian pharmaceutical company with a strong OTC and prescription portfolio. Comparable as a domestic competitor in analgesics, anti-inflammatories, and consumer health categories.
• Biolab Farmacêutica: Brazilian pharmaceutical manufacturer with prescription and OTC products distributed nationally. Comparable scale and distribution model targeting Brazilian retail pharmacies.
• Medley (Sanofi): Brazilian generic pharmaceutical brand owned by Sanofi, focused on prescription and OTC generics. Direct comparable in the Brazilian generic/similar medicines segment.
• Eurofarma: Brazilian multinational pharmaceutical manufacturer with a generics, similars, and OTC portfolio across Latin America. Comparable business model (manufacturing + distribution) and overlapping therapeutic categories.

Emerging players

• Aurobindo Pharma: Indian-headquartered global generic manufacturer with growing Brazil and LatAm operations. Comparable as a low-cost generic competitor targeting similar therapeutic classes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/203737553112730
• LinkedInlinkedin.com/company/multilab---ind--e-com--de-prod--farmac-uticos

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Multilab